Abstract Library

#2683 Clinicopathological Features and Prognostic Analysis of 227 Cases with Well-Differentiated Gastric Neuroendocrine Tumors

Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a group of rare tumors with a strong heterogeneity, subdivided as well-differentiated neuroendocrine tumors (NETs, type 1-3 g-NETs) and poorly-differentiated neuroendocrine carcinoma(NECs). WHO classification(2019) for digestive system tumours has carried out a new classification and grading criteria for NENs of the gastrointestinal tract recently, there is very few relevant clinical data based on this new classification, especially for gastric NETs(g-NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Li Y, Tan H, Jie C, Jie L, Pan Z,

Keywords: clinicopathological features, prognostic analysis, well-differentiated gastric neuroendocrine tumors, grade, type,

#2211 Clinicopathologic Characteristics of Chinese Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: Results of a Nation-Wide Retrospective Epidemiology Study

Introduction: he rare incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has contributed to a paucity of large epidemiologic studies of patients with this condition, especially in China.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yu P, Chi Y, Shi S, Chen Y, Jiang L,

Keywords: gastroenteropancreatic neuroendocrine neoplasms, clinicopathological characteristics, immunohistochemical staining,

#1701 Characteristics of Bronchopulmonary Carcinoids in Cancer Centre Database in Moscow

Introduction: Bronchopulmonary carcinoids (BC) represent 1% of lung cancers and comprise typical (TC), atypical carcinoids (AC), small cell lung cancer (SCLC) and large cell cancer.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Komarova L, Arion A, Pirogova N, Tabolinovskaya T,

Keywords: registry, lung,

#1327 Is Screening of Young Asymptomatic MEN1 Patients Necessary?

Introduction: Recent clinical practice guidelines recommend that routine screening of MEN1 mutation carriers should start at the age of 5 years to detect MEN1-associated tumors which is controversial in the scientific community.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Manoharan J, Lopez C, Albers M, Bollmann C, Slater E,

Keywords: Screening, MEN1,

#185 Czech Neuroendocrine Registry - First Results

Introduction: The Czech Neuroendocrine Registry was started in October 2009 as a platform that should facilitate the data based on communication among various specialists treating NETs.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Barkmanova J, Novak J, Vitek P, Sedlackova E, Honova H,

Keywords: neuroendocrine registry, population-based system, neuroendocrine tumors (NETs),